N,N- diethyl- 4- (5- hydroxyspiro(chromene- 2,4'- piperidine)- 4- yl)benzamide

09/24/2009 - "The lead derivative, ADL5859 (4), is currently in phase II proof-of-concept studies for the management of pain. "
02/01/2017 - "ADL5859 and ADL5747 entered clinical trials and successfully passed phase I. However, in phase II studies the primary endpoint (pain reduction) was not met and further investigation was terminated. "
09/01/2012 - "In conclusion, both ADL5859 and ADL5747 showed efficient pain-reducing properties in the two models of chronic pain. "
09/01/2012 - "We tested analgesic effects of ADL5859 and ADL5747 in mice by using mechanical sensitivity measures in both complete Freund's adjuvant and sciatic nerve ligation pain models. "
10/09/2008 - "Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859)."

09/01/2012 - "In conclusion, both ADL5859 and ADL5747 showed efficient pain-reducing properties in the two models of chronic pain. "
09/01/2012 - "N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5859) and N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5747) are novel δ-opioid agonists that show good oral bioavailability and analgesic and antidepressive effects in the rat and represent potential drugs for chronic pain treatment. "

06/15/2016 - "ADL5859 is a selective nonpeptide DOP receptor agonist which does not produce seizures and EEG disturbances. "

09/01/2012 - "Both ADL5859 and ADL5747, and the prototypical δ agonist 4-[(R)-[(2S,5R)-4-allyl-2,5-dimethyl-piperazin-1-yl]-(3-methoxyphenyl)methyl]-N,N-diethyl-benzamide (SNC80) as a control, significantly reduced inflammatory and neuropathic pain. "